Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 22, 2010

AstraZeneca Withdraws BLA for Prophylactic Use of mAb in RSV

AstraZeneca Withdraws BLA for Prophylactic Use of mAb in RSV

Firm incurs $455 million charge but will continue developing the antibody for RSV.[krishnacreations-Fotolia.com]

  • AstraZeneca will incur a financial impairment charge of $455 million before the end of this year as a result of biologics unit MedImmune pulling the BLA for approval of the monoclonal antibody motavizumab in the prophylaxis of serious respiratory syncytial virus (RSV) disease. The firm said it will discontinue further development of motavizumab for the prophylaxis indication but will continue its development for other RSV therapy.

    MedImmune, AstraZeneca’s biologics unit,  filed the original motavizumab prophylaxis BLA in January 2008 and received its first complete response letter from FDA in November 2008. Motavizumab was reviewed by FDA’s Antiviral Drugs Advisory Committee in June 2010, and the the agency subsequently issued a second CRL requesting additional clinical data. As a result, MedImmune has now decided to discontinue certain motavizumab development paths and withdraw the prophylaxis BLA from the FDA.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »